LY2444296
Modify Date: 2024-01-10 18:00:45
LY2444296 structure
|
Common Name | LY2444296 | ||
|---|---|---|---|---|
| CAS Number | 1346133-11-6 | Molecular Weight | 408.44 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H22F2N2O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LY2444296LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects[1][2]. |
| Name | LY2444296 |
|---|---|
| Synonym | More Synonyms |
| Description | LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Ki: ~1 nM (KOPR)[1] |
| In Vivo | LY2444296 displays anti-anxiety like effects in the EPM test[1]. LY2444296 (3 mg/kg; i.p.; 30 min before U69,593 administration) prevents behavioral and neuroendocrine effects caused by the reference kappa agonist U69,593 in cocaine-naïve rats[2]. LY2444296 reduces anxiety-like and depressive-like behaviors, as well as CORT release, in rats tested after chronic extended access cocaine self-administration, but not in cocaine-naïve rats[2]. Animal Model: Adult male Sprague Dawley rats (240–250 g)[2] Dosage: 3 mg/kg Administration: Injected intraperitoneally; 30 min before U69,593 administration Result: Prevented behavioral and neuroendocrine effects caused by U69,593 in cocaine-naïve rats. |
| References |
| Molecular Formula | C24H22F2N2O2 |
|---|---|
| Molecular Weight | 408.44 |
| Hazard Codes | Xi |
|---|
| MFCD32067413 |